Stay updated on Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.

Latest updates to the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedStudy status updated to Completed with actual completion date 2025-10-30 and last update posted 2025-11-20. Principal investigator changed from Jad Cuahoud, MD to Jon Chatzkel, MD.SummaryDifference0.5%

- Check27 days agoChange DetectedAdded branding for the Moffitt Cancer Center Clinical Trials website and a 'Helpful Links Provided by' section. Removed the government funding status notice.SummaryDifference0.6%

- Check49 days agoChange DetectedThe changes are limited to visual/layout adjustments and minor metadata updates; no core study information appears to be modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedThe page now includes newer date references (October 2025) and an 'Estimated Last Update Posted' item, while removing earlier June 2025 dates. This signals an update to the page's recency and last-update messaging.SummaryDifference0.5%

- Check70 days agoChange DetectedAdded a government operations status notice and updated the version to v3.2.0; removed the v3.1.0 version reference.SummaryDifference3%

- Check77 days agoChange DetectedUpdated revision from v3.0.2 to v3.1.0, indicating a new version release with no other content changes.SummaryDifference0.1%

Stay in the know with updates to Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.